


Supplement figure S2. Uncertainty in model predictions of the relative impact of HPV vaccination and cervical screening for all women - among all women: Predicted relative decrease in age-standardised cervical cancer incidence over time among all women compared to *basecase* after A) girls' vaccination (Sc1) and B) girls' vaccination and 2 lifetime cervical screens (Sc3) introduced in 2020. Solid line and shaded area represent the median and 90% uncertainty interval for each model, respectively. *Det_HIV-HPV* and *MicroCOSM-HPV* are models of South Africa and the *DRIVE* model if for KZN.

Vaccine coverage=90%, Vaccine efficacy=100% against HPV16/18/31/33/45/52/58, Vaccine duration=Lifetime; Screening=HPV testing, Screening uptake= 45% (2023-2029), 70% (2030-2044), 90% (2045+). Treatment efficacy=100%, Lost to follow-up=10%.

A) Girls' vaccination



B) Girls' vaccination and 2 lifetime screens

